Combined antihypertensive and lipid-lowering treatment.
Hypertension and hypercholesterolemia are frequently associated, and their treatment is proven to reduce cardiovascular risk. Current guidelines on cardiovascular prevention strongly recommend treating both disorders. Unfortunately, the low treatment and control rates, combined with the high prevalence of both conditions, still contribute to the high burden of cardiovascular disease in Western countries. In the past 5 years, many studies evaluating the benefit of combined antihypertensive and lipid-lowering treatment on endothelial dysfunction, coronary atherosclerosis, hypertension control, and on primary and secondary prevention of cardiovascular events have been published. In this article, we discuss and critically evaluate the available evidence on the potential benefits of combined antihypertensive and lipid-lowering treatment.
Cesari
Maurizio
M
Department of Clinical and Experimental Medicine, Clinica Medica 4, University of Padova, via Giustiniani, 2, 35126 Padova, Italy. mcesari@hotmail.com
Pessina
Achille C
AC
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000517:prevention & control; D015897:Comorbidity; D004359:Drug Therapy, Combination; D004730:Endothelium, Vascular / Q000502:physiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000453:epidemiology*; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology*; D009543:Nifedipine / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D019821:Simvastatin / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011725:Pyridines; D019821:Simvastatin; C086276:cerivastatin; D009543:Nifedipine